CytoMed Therapeutics Limited (GDTC) Stock price, Description, News & Info

#Thinksabio latest news

Update On Clinical Trial Milestone – CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies